Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 10, 2015 07:30 ET | Source: Melinta Therapeutics, Inc.

Cempra to Present Data From Antibiotic Drug Development Programs at ICAAC/ICC 2015 Meeting

CHAPEL HILL, N.C., Sept. 10, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
September 08, 2014 15:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics Demonstrates Potent In Vitro Activity of New Antibiotic Class against Gram Negative ESKAPE Pathogens

NEW HAVEN, Conn, Sept. 8, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today provided an update on the Company's innovative ESKAPE Pathogen Program. The ESKAPE Pathogen Program leverages Melinta's...
September 06, 2014 12:01 ET | Source: Melinta Therapeutics

Melinta Therapeutics and Hartford Hospital Demonstrate Delafloxacin's Potent In-Vitro Activity against Complicated Urinary Tract Infection Pathogens

NEW HAVEN, Conn, Sept. 6, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics and Hartford Hospital today announced in vitro results from an investigator-sponsored study that highlight delafloxacin's...
August 27, 2013 08:00 ET | Source: Fedora Pharmaceuticals, Inc.

Fedora Pharmaceuticals Unveils Details of Antibiotic Resistance Program in 10 Posters at 2013 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

EDMONTON, Alberta, Aug. 27, 2013 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. today announced that the Company and its collaborators will be presenting 10 posters at the upcoming Interscience...
August 22, 2013 09:57 ET | Source: ContraFect Corporation

ContraFect Corporation Showcases CF-301 at ICAAC 2013 Meeting in Denver, CO

YONKERS, NY--(Marketwired - Aug 22, 2013) - ContraFect Corporation, developing biotherapeutics for life-threatening infectious diseases, is pleased to announce that ContraFect has been selected to...